Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T19:52:12.904Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:52:12.904Z.

Quote observation: 2026-10-06T19:50:39.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 3.7486
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.427

FMP input reference: 8e2f3ec51e074b036058196f7f903a3cac1545bb57f25a27b7ce4fd0c255fbf9

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

GALT PE Ratio Metrics

PE RATIO

N/A

PE RATIO AVG TTM

N/A

PE RATIO AVG 3Y

N/A

PE RATIO AVG 5Y

N/A

PE RATIO AVG 10Y

N/A

PE RATIO AVG 15Y

N/A

PE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

N/A

CURRENT VS 3Y AVG

N/A

CURRENT VS 5Y AVG

N/A

CURRENT VS 10Y AVG

N/A

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

GALT Competitors' PE Ratio

GALT

Galectin Therapeutics Inc.

Current

Market Cap

$246.87M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CAMP

CAMP4 Therapeutics Corporation

vs GALT

Market Cap

$246.62M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLGL

Sol-Gel Technologies Ltd.

vs GALT

Market Cap

$242.09M

PE Ratio

N/A

TTM Avg

50.66

3Y Avg

50.25

5Y Avg

404.96

LFCR

Lifecore Biomedical, Inc.

vs GALT

Market Cap

$241.94M

PE Ratio

N/A

TTM Avg

80.39

3Y Avg

80.39

5Y Avg

80.39

QTTB

Q32 Bio Inc.

vs GALT

Market Cap

$241.68M

PE Ratio

2.91

TTM Avg

4.27

3Y Avg

4.27

5Y Avg

3.78

UPB

Upstream Bio, Inc.

vs GALT

Market Cap

$250.63M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IPSC

Century Therapeutics, Inc.

vs GALT

Market Cap

$239.92M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HITI

High Tide Inc.

vs GALT

Market Cap

$238.57M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

QSI

Quantum-Si incorporated

vs GALT

Market Cap

$238.38M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AKBA

Akebia Therapeutics, Inc.

vs GALT

Market Cap

$236.09M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Galectin Therapeutics Inc. (GALT)	$246.87M	N/A	N/A	N/A	N/A
CAMP4 Therapeutics Corporation (CAMP)vs ›	$246.62M	N/A	N/A	N/A	N/A
Sol-Gel Technologies Ltd. (SLGL)vs ›	$242.09M	N/A	50.66	50.25	404.96
Lifecore Biomedical, Inc. (LFCR)vs ›	$241.94M	N/A	80.39	80.39	80.39
Q32 Bio Inc. (QTTB)vs ›	$241.68M	2.91	4.27	4.27	3.78
Upstream Bio, Inc. (UPB)vs ›	$250.63M	N/A	N/A	N/A	N/A
Century Therapeutics, Inc. (IPSC)vs ›	$239.92M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$238.57M	N/A	N/A	N/A	N/A
Quantum-Si incorporated (QSI)vs ›	$238.38M	N/A	N/A	N/A	N/A
Akebia Therapeutics, Inc. (AKBA)vs ›	$236.09M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$3.75

÷

Forward EPS (Est.)

$-0.30

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

GALT PE Ratio History

DATE	PE RATIO
2007-11-14	4.20
2007-11-13	4.53
2007-11-12	4.53
2007-11-09	4.53
2007-11-08	4.53
2007-11-07	4.59
2007-11-06	4.53
2007-11-05	4.42
2007-11-02	4.48
2007-11-01	4.37
2007-10-31	4.48
2007-10-30	4.04
2007-10-29	3.92
2007-10-26	3.70
2007-10-25	3.59
2007-10-24	3.43
2007-10-23	3.70
2007-10-22	3.54
2007-10-19	3.48
2007-10-18	3.37
2007-10-17	3.54
2007-10-16	3.43
2007-10-15	3.43
2007-10-12	3.70
2007-10-11	3.59
2007-10-10	4.20
2007-10-09	4.42
2007-10-08	4.37
2007-10-05	4.92
2007-10-04	4.42
2007-10-03	4.09
2007-10-02	3.98
2007-10-01	3.98
2007-09-28	3.70
2007-09-27	3.65
2007-09-26	3.92
2007-09-25	3.98
2007-09-24	3.76
2007-09-21	3.10
2007-09-20	2.60
2007-09-19	2.82
2007-09-18	2.87
2007-09-17	2.82
2007-09-14	2.32
2007-09-13	1.77
2007-09-12	1.71
2007-09-11	1.71
2007-09-10	1.71
2007-09-07	1.93
2007-09-06	2.05
2007-09-05	1.82
2007-09-04	1.88
2007-08-31	1.93
2007-08-30	1.93
2007-08-29	1.93
2007-08-28	1.99
2007-08-27	2.10
2007-08-24	2.10
2007-08-23	2.16
2007-08-22	2.27
2007-08-21	2.16
2007-08-20	2.21
2007-08-17	2.16
2007-08-16	2.10
2007-08-15	2.16
2007-08-14	2.16
2007-08-13	2.16
2007-08-10	2.22
2007-08-09	2.28
2007-08-08	2.28
2007-08-07	2.17
2007-08-06	2.28
2007-08-03	2.28
2007-08-02	2.17
2007-08-01	2.28
2007-07-31	2.33
2007-07-30	2.44
2007-07-27	2.22
2007-07-26	2.28
2007-07-25	2.28
2007-07-24	2.50
2007-07-23	2.33
2007-07-20	2.06
2007-07-19	2.33
2007-07-18	2.39
2007-07-17	2.50
2007-07-16	2.39
2007-07-13	2.50
2007-07-12	2.67
2007-07-11	2.72
2007-07-10	2.78
2007-07-09	3.00
2007-07-06	2.78
2007-07-05	2.83
2007-07-03	3.17
2007-07-02	2.78
2007-06-29	1.94
2007-06-28	2.11
2007-06-27	2.39

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

GALT PE Ratio Chart

GALT PE Ratio Metrics

GALT Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

GALT PE Ratio History

Related Metrics